Shire Pharmaceuticals News
Most Popular Shire Pharmaceuticals Story
Shire ready to undercut Cerezyme price by 15%
A price war could be shaping up for Gaucher disease. With its PDUFA date looming, Shire says that it plans to market its new therapy under the name VPRIV (it was developed as velaglucerase alfa), and... Read more...
Latest Headlines
- February 19, 2010
- February 12, 2010
- February 11, 2010
- December 10, 2009
- October 30, 2009
- September 11, 2009
- September 1, 2009
- August 24, 2009
- August 20, 2009
- August 3, 2009
- April 17, 2009
- October 10, 2008
- July 3, 2008
- March 3, 2008
- November 8, 2007
- November 6, 2007
- October 1, 2007
- September 11, 2007
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
